Fig 1: Effect of LPS treatment on miR-28-5p expression, proliferation, and inflammation. A. RT-qPCR experiments confirmed that LPS treatment increased miR-28-5p levels. B. CCK-8 was employed to detect the effect of LPS on cell proliferation. C. ELISA was conducted to detect the regulation of inflammatory factors IL-6 (C) and IL-1β (D) by LPS inducted. All experiments were conducted in triplicate. ∗∗∗P < 0.001 vs. control group.
Fig 2: Increased miR-28-5p significantly attenuated LPS-induced damage in PDLCs. A. RT-qPCR was used to examine the level of miR-28-5p in PDLCs transfected with miR-28-5p mimic or inhibitor. B. Regulation of miR-28-5p levels in LPS treated cells after transfection with miR-28-5p mimic. Regulation of LPS-induced cell proliferation (C) and levels of inflammatory factors IL-6 (D) and IL-1β (E). All experiments were conducted in triplicate. ∗∗∗P < 0.001 vs. control group; ##P < 0.01, ###P < 0.001 vs. compared with LPS + miR-NC.
Fig 3: The proinflammatory cytokines were elevated in ALI patients. The concentrations of cytokines including IL-1β (A), IL-6 (B), IL-15 (C), TNF-α (D), IL-4 (E), and IL-13 (F) were measured using ELISA kits in serum samples obtained from 24 NSCLC patients (Control) under T0 stage and 24 ALI patients. ***P < 0.001.
Fig 4: Receiver operating characteristic (ROC) curves for IL-1 (A), IL-6 (B), and TNF-α (C) in distinguishing HF patients from controls.
Supplier Page from Abcam for Human IL-6 ELISA Kit